Surveillance and management of multidrug-resistant microorganisms

References

• Curcio D, Fernandez F, Vergara G, Vazquez W, Luna CM. Late-onset ventilator-associated pneumonia due to Acinetobacter spp: experience with tigecycline. J. Chemother.29, 58–62 (2009).
   Google Scholar
• Curcio D. Tigecycline for severe infections: the gap between the warning and the necessity. J. Antimicrob. Chemother.66(2), 454–456 (2011).
   PubMed Web of Science ®Google Scholar
• Loeffler CA, MacDougall C. Update on prevalence and treatment of methicillin resistant Staphylococcus aureus infections. Expert Rev. Anti Infect. Ther.55, 961–981 (2008).
   Google Scholar
• Pantosti A, Venditti M. What is MRSA? Eur. Respir. J.34, 1190–1196 (2009).
   PubMed Web of Science ®Google Scholar
• Rossolini GM, Mantengoli E, Montagnani F, Pollini S. Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents. Curr. Opin. Microbiol.13(5), 582–588 (2010).
   PubMed Web of Science ®Google Scholar
• Hidron AI, Edwards JR, Patel J et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the national healthcare safety network at centers for disease control and prevention 2006–2007. Infect. Control Hosp. Epidemiol.29, 996–1011 (2008).
   PubMed Web of Science ®Google Scholar
• Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann. Clin. Microbiol. Antimicrob.5, 2 (2006).
   PubMedGoogle Scholar
• Kobayashi H. National hospital infection surveillance on methicillin-resistant Staphylococcus aureus. J. Hosp. Infect.60, 172–175 (2005).
   PubMed Web of Science ®Google Scholar
• Collignon P, Nimmo GR, Gottlieb T, Gosbell IB. Australian Group on Antimicrobial Resistance. Staphylococcus aureus bacteremia, Australia. Emerg. Infect. Dis.11, 554–561 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenthal VD, Maki DG, Jamulitrat S et al. International nosocomial infection control consortium (INICC) report, data summary for 2003–2008, issued June 2009. Am. J. Infect. Control38(2), 95–104 (2010).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, DeCorby M, Laing N et al. Antimicrobial-resistant pathogens in intgensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005–2006. Antimicrob. Agents Chemother.52(4), 1430–1437 (2008).
   PubMed Web of Science ®Google Scholar
• Gorwitz RJ, Kruszon-Moran D, McAllister SK et al. Changes in the prevalence of Staphylococcus aureus nasal colonization in the United States, 2001–2004. J. Infect. Dis.197, 1226–1234 (2008).
   PubMed Web of Science ®Google Scholar
• Kluytmans-VandenBergh MF, Kluytmans JA. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin. Microbiol. Infect.12(Suppl. 1), 9–15 (2006).
   PubMed Web of Science ®Google Scholar
• Jansen WTM, van der Bruggen JT, Verhoef J, Fluit AC. Bacterial resistance: a sensitive issue complexity of the challenge and containment strategy in Europe. Drug Resis. Updat.9, 123–133 (2006).
   PubMed Web of Science ®Google Scholar
• Ratnaraja NVDV, Hawkey PM. Current challenges in treating MRSA: what are the options? Expert Rev. Anti Infect. Ther.6, 601–618 (2008).
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med.352, 1436–1444 (2005).
   PubMed Web of Science ®Google Scholar
• Millar BC, Loughrey A, Elborn JS, Moore JE. Proposed definitions of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). J. Hosp. Infect.67, 109–113 (2007).
   PubMed Web of Science ®Google Scholar
• Elston JW, Barlow GD. Community-associated MRSA in United Kingdom. J. Infect.59(3), 149–155 (2009).
   PubMed Web of Science ®Google Scholar
• Harbarth S, Francois P, Schrenzel J et al. Community-associated methicillin-resistant Staphylococcus aureus, Switzerland. Emerg. Infect. Dis.11, 962–965 (2005).
   PubMed Web of Science ®Google Scholar
• Orsi GB, Mastroianni CM, Giordano A, Monaco M, Venditti M. Lack of community-associated MRSA in Rome. J. Hosp. Infect.71(4), 374–376 (2009).
   PubMed Web of Science ®Google Scholar
• Witte W. Community acquired methicillin-resistant Staphylococcus aureus: what do we need to know? Clin. Microbiol. Infect.15(Suppl.), 17–25 (2009).
   PubMed Web of Science ®Google Scholar
• Otter JA, French GL. Molecular epidemiology of community-associated mehicillin-resistant Staphylococcus aureus in Europe. Lancet Infect. Dis.10, 227–239 (2010).
   PubMed Web of Science ®Google Scholar
• Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis.46, S344–S349 (2008).
   PubMed Web of Science ®Google Scholar
• Chini V, Petinaki E, Meugnier H et al. Emergence of a new clone carrying Panton-Valentine leukocidin genes and staphylococcal cassette chromosome mec type V among methicillin-resitant Staphylococcus aureus in Greece. Scand. J. Infect. Dis.40(5), 368–372 (2008).
   PubMed Web of Science ®Google Scholar
• Seybold U, Kourbatova EV, Johnson JG et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated bloodstream infections. Clin. Microbiol. Infect.42, 647–656 (2006).
   Google Scholar
• Valsesia G, Rossi M, Bertschy S, Pfyffer GE. Emergence of SCCmec type IV and SCCmec type V methicillin-resistant Staphylococcus aureus containing the Panton–Valentine leukocidin genes in a large academic teaching hospital in central Switzerland: external invaders or persisting circulators? J. Clin. Microbiol.48(3), 720–727 (2010).
   PubMed Web of Science ®Google Scholar
• McCarthy NL, Sullivan PS, Gaynes R, Rimland D. Healthcare associated and community-associated methicillin-resistant Staphylococcus aureus infections: a comparison of definitions. Am. J. Infect. Control38(8), 600–606 (2010).
   PubMed Web of Science ®Google Scholar
• Nichol KA, Adam HJ, Hussain Z et al. comparison of community-associated asnd healthcare-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007–2009 study. Diagn. Microbiol. Infect. Dis.69(3), 320–325 (2011).
   PubMed Web of Science ®Google Scholar
• Park SH, Park C, Yoo JH et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated bloodstream infections in Korea. Infect. Control Hosp. Epidemiol.30(2), 146–155 (2009).
   PubMed Web of Science ®Google Scholar
• Milstone AM, Carroll KC, Ross T, Shangraw KA, Perl TM. Community-associated methicillin-resistant Staphylococcus aureus strains in pediatric intensive care unit. Emerg. Infect. Dis.16(4), 647–655 (2010).
   PubMed Web of Science ®Google Scholar
• Rupp ME, Fey PD. Staphylococcus epidermidis and other coagulase negative staphylococci. In: Principles and Practice of Infectious Diseases. 7th Edition. Mandell GP, Bennett JE, Dolin R (Eds). Churchill Livingstone Elsevier, PA, USA, 2579–2589 (2010).
   Google Scholar
• Nathwani D. Health economia issues in the treatment of drug-resistant serious Gram-positive infections. J. Infect.59(S1), S40–S50 (2009).
   PubMed Web of Science ®Google Scholar
• Shorr AF. Epidemiology and economic impact of methicillin-resistant Staphylococcus aureus. Pharmacoeconomics25(9), 751–768 (2007).
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. the impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay and hospital charges. Infect. Control Hosp. Epidemiol.26(2), 166–174 (2005).
   PubMed Web of Science ®Google Scholar
• Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn. Microbiol. Infect. Dis.52, 113–122 (2005).
   PubMed Web of Science ®Google Scholar
• Shorr AF, Lodise T. Burden of methicillin-resistant Staphylococcus aureus on healthcare cost and resource utilization. ISMR Update1, 4–11 (2006).
   Google Scholar
• Filice GA, Nyman JA, Lexau C, Lees CH, Bockstedt LA, Como-Sabetti K. Excess costs for utilization with methicillin resistance for patients with Staphylococcus aureus infection. Infect. Control Hosp. Epidemiol.31, 365–373 (2010).
   PubMed Web of Science ®Google Scholar
• Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y, Sloane R. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PloS ONE4(12), e8305 (2009).
   PubMed Web of Science ®Google Scholar
• Benfield T, Espersen F, Frimodt-Moller N, Jensen AG, Larsen AR, Pallesen LV. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin. Microbiol. Infect.13, 257–263 (2007).
   PubMed Web of Science ®Google Scholar
• Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA298(15), 1763–1771 (2007).
   PubMed Web of Science ®Google Scholar
• Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes and influence of methicillin resistance in Calgary, Canada, 2000–2006. J. Infect. Dis.198, 336–343 (2008).
   PubMed Web of Science ®Google Scholar
• Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophisiology and management strategies. Clin. Infect. Dis.48, 231–237 (2009).
   PubMed Web of Science ®Google Scholar
• Uslan DZ, Crane SJ, Steckelberg JM, Cockerill FRJr, St Sauver JL, Stoner S. Age and sex associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. Arch. Intern. Med.49(18), 1851–1859 (2007).
   Google Scholar
• Shorr AF, Combes A, Kollef MH, Chastre J. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit. Care Med.34, 700–706 (2006).
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchamer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis.36, 53–59 (2003).
   PubMed Web of Science ®Google Scholar
• Engemann JJ, Carmeli Y. Cosgrove SE et al. Adverse clinical economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis.36(5), 592–598 (2003).
   PubMed Web of Science ®Google Scholar
• Safdar N, Bradley EA. The risk of infection after nasal colonization with Staphylococcus aureus. Am. J. Med.121, 310–315 (2008).
   PubMed Web of Science ®Google Scholar
• Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care–associated pneumonia: results from a large US database of culture-positive pneumonia. Chest128, 3854–3862 (2005).
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis.46(Suppl. 5), S378–S385 (2008).
   PubMed Web of Science ®Google Scholar
• Niederman MS. Treatment options for nosocomial pneumonia due to MRSA. J. Infect.59(Suppl. 1), S25–S31 (2009).
   PubMed Web of Science ®Google Scholar
• Haque NZ, Cahuayme Zuniga L, Peyrani P et al. Relationship of vancomycin MIC to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Chest138(6), 1356–1362 (2010).
   PubMed Web of Science ®Google Scholar
• Francis JS, Doherty MC, Lopatin U et al. severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton–Valentine leukocidin genes. Clin. Infect. Dis.40, 100–107 (2005).
   PubMed Web of Science ®Google Scholar
• Miller LG, Perdreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med.352, 1445–1453 (2005).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicco E, Malgorzata M, Viscoli C, Valbusa A, Bongiorno D. Community associated methicillin resistant Staphylococcus aureus (CA-MRSA) infective endocarditis in Italy. J. Infect.61(4), 353–355 (2010).
   PubMedGoogle Scholar
• Favre B, Hugonnet S, Correa L, Sax H, Rohner P, Pittet D. Nosocomial bacteremia: clinical significance of a single blood culture positive for coagulase-negative staphylococci. Infect. Control Hosp. Epidemiol.26, 697–702 (2005).
   PubMed Web of Science ®Google Scholar
• Wang A, Athan E, Pappas PA et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA297(12), 1354–1361 (2007).
   PubMed Web of Science ®Google Scholar
• Chu VH, Woods CW, Miro JM et al. Emergence of coagulase negative staphylococci as a cause of native valve endocarditis. Clin. Infect. Dis.46(2), 232–242 (2008).
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Szczech LA, Benjamin DK Jr et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis.44(2), 190–196 (2007).
   PubMed Web of Science ®Google Scholar
• Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J. Antimicrob. Chemother.57(4), 589–608 (2006).
   PubMed Web of Science ®Google Scholar
• Naber CK, Baddour LM, Giamarellos-Bourboulis EJ et al. Clinical Consensus Conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin. Infect. Dis.48, S260–S270 (2009).
   PubMed Web of Science ®Google Scholar
• Boucher H, Miller LG, Rozonable RR. Serious infections caused by methcillin-resistant Staphylococcus aureus. Clin. Infect. Dis.51(Suppl. 2), 183–197 (2010).
   PubMed Web of Science ®Google Scholar
• Lin MY, Hayden MK. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus: recognition and prevention in intensive care units. Crit. Care Med.38(Suppl.), S335–S344 (2010).
   PubMed Web of Science ®Google Scholar
• Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis.1, 147–155 (2001).
   PubMedGoogle Scholar
• Tenover F, Biddle J, Lancaster M. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis.7, 327–332 (2001).
   PubMed Web of Science ®Google Scholar
• Sievert DM, Rudrick JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resitant Staphylococcus aureus in the United States, 2002–2006. Clin. Infect. Dis.46, 668–774 (2008).
   PubMed Web of Science ®Google Scholar
• Lalueza A, Vhaves F, San Juan R, Daskalaki M, Otero JR, Aguado JM. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J. Infect. Dis.201(2), 311–312 (2010).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Pillai S, Mylonakis E, Moellering RC, Eliopoulos GM. Reply to Lalueza A et al.J. Infect. Dis.201(2), 312–313 (2010).
   Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis.46, 193–200 (2008).
   PubMed Web of Science ®Google Scholar
• Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin. Infect. Dis.48, 997–998 (2009).
   PubMed Web of Science ®Google Scholar
• Tenover FC, Moellering RC Jr. The rationale of revising the clinical and laboratory standars institute vancomycin minimal inhibitory concentration interpretative criteria for Staphylococcus aureus. Clin. Infect. Dis.44, 1208–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. Reduced glycopeptides susceptibility in methicillin resistant Staphylococcus aureus. Int. J. Antimicrob. Agents30, 398–408 (2007).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moellering RC Jr. Increasing atbiotic resistance among methicillin resistant Staphylococcus aureus strains. Clin. Infect. Dis.46, S360–S367 (2008).
   PubMed Web of Science ®Google Scholar
• Lodise TP, Graves J, Evans A. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother.52, 3315–3320 (2008).
   PubMed Web of Science ®Google Scholar
• Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, Garau J. Management of serious methicillin-resistant Staphylococcus aureus infections: what are the limits? Int. J. Antimicrob. Agents37(3), 202–209 (2011).
   PubMed Web of Science ®Google Scholar
• Bongiorno D, Campanile F, Mongelli G et al. DNA methylase modifications and other linezolid resistance mutations in coagulase-negative staphylococci in Italy. J. Antimicrob. Chemother.65(11), 2336–2340 (2010).
   PubMed Web of Science ®Google Scholar
• Takeuchi F, Watanabe S, Baba T et al. Whole-genome sequencing of Staphylococcus haemolyticus uncovers the extreme plasticity of its genome in evolution of human-colonizing staphylococcal species. J. Bacteriol.187, 7292–7308 (2005).
   PubMed Web of Science ®Google Scholar
• Raponi G, Ghezzi MC, Gherardi G et al. Antimicrobial susceptibility, biochemical and genetic profiles of Staphylococcus haemolyticus strains from the bloodstream of patients hospitalized in critical care units. J. Chemother.26, 264–269 (2005).
   Google Scholar
• Santos Sanches I, Mato R, de lencastre H, Tomasz A. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase positive and coagulase negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Microb. Drug Resist.6, 199–211 (2000).
   PubMed Web of Science ®Google Scholar
• Falcone M, Giannella M, Raponi G, Mancini C, Venditti M. Teicoplanin use and emergence of Staphylococcus haemolyticus: is there a link? Clin. Microbiol. Infect.12, 96–97 (2006).
   PubMed Web of Science ®Google Scholar
• Rehm SJ, Tice A. Staphylococcus aureus: methicillin-susceptible S. aureus to methicillin-resistant S.aureus and vancomycin-resistant S. aureus. Clin. Infect. Dis.51(S2), S176–S182 (2010).
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Chastre J, Craig WA et al. Guidelines for the management of adults with hospital acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med.171, 388–416 (2005).
   PubMed Web of Science ®Google Scholar
• Villani P, Regazzi MB, Marubbi F et al. cerebrospinal fluid linezolid concentration in postneurosurgical central nervous system infections. Antimicrob. Agents Chemother.46, 936–937 (2002).
   PubMed Web of Science ®Google Scholar
• Adembri C, Fallani S, Cassetta MI et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int. J. Antimicrob. Agents31(2), 122–129 (2008).
   PubMed Web of Science ®Google Scholar
• Monaco M, Antonucci R, Palange P, Venditti M, Pantosti A. Methicillin-resistant Staphylococcus aureus necrotizing pneumonia. Emerg. Infect. Dis.11, 1647–1648 (2005).
   PubMed Web of Science ®Google Scholar
• Boucher HW. Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication. Clin. Infect. Dis.50(Suppl. 1), S4–S9 (2010).
   PubMed Web of Science ®Google Scholar
• Mermel LA, Allon M, Bouza E et al. Clinical practice guidelines for the diagnosis of intravascular catheter-related infection: 2009 update by the Infectious Diseases of America. Clin. Infect. Dis.49, 1–45 (2009).
   PubMed Web of Science ®Google Scholar
• Gudiol F, Aguado JM, Pascual A et al. Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistant Staphylococcus aureus. Enferm. Infecc. Microbiol. Clin.27(2), 105–115 (2009).
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE et al. clinical practice guidelines by the infectious Diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adukts and children. Clin. Infect. Dis.52(3), e18–e55 (2011).
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteraemia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med.355, 653–665 (2006).
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin. Infect. Dis.49, 1908–1914 (2009).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Calic D, Schweeizer F et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin, and telavancin. Drugs70, 859–886 (2010).
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Lalani T, Corey GR et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin. Infect. Dis.52(1), 31–40 (2011).
   PubMed Web of Science ®Google Scholar
• Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker endocarditis lead infective endocarditis with telavancin. Antimicrob. Agents Chemother.54, 5376–5378 (2010).
   PubMed Web of Science ®Google Scholar
• Nace H, Lorber B. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J. Antimicrob. Chemother.65, 1315–1316 (2010).
   PubMed Web of Science ®Google Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis.41(Suppl. 5), S354–S367 (2005).
   PubMed Web of Science ®Google Scholar
• Bazan JA, Martin SI. Ceftaroline fosafamil: a novel broad-spectrum cephalosporin. Drugs Today46(10), 743–755 (2010).
   PubMed Web of Science ®Google Scholar
• Zhanel CG, Rossnagel E, Nickol K et al. Ceftazidime pharmaco-dynamic activity versus community-associated and healthcare-associated methicillin resistant Staphylococcus aureus, heteroresistant vancomycin intermediate S. aureus, vancomycin intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model. J. Antimicrob. Chemother.66, 1301–1305 (2011).
   PubMed Web of Science ®Google Scholar
• Esposito S, Leone S, Bassetti M et al. Italian guidelines for the diagnosis and infectious disease management of osteomyelitis and prosthetic joint infections in adults. Infection37, 478–496 (2009).
   PubMed Web of Science ®Google Scholar
• Leone S, Borrè S, Monforte A et al. Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. Int. J. Infect. Dis.14(Suppl. 4), S67–S77 (2010).
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J. Infect.60(6), 440–451 (2010).
   PubMed Web of Science ®Google Scholar
• Jones RN, Yeaman MR, Sakoulas G et al. Failure in clinical treatment of Staphylococcus aureus infection with daptomycin associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemther.52, 269–278 (2008).
   PubMed Web of Science ®Google Scholar
• Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin and linezolid in methicillin-resistant Staphylococcus aureus. Curr. Opin. Pharmacol.10, 1–6 (2010).
   PubMed Web of Science ®Google Scholar
• Ikeda-Dantsuji T, Hanaki H, Sakai F et al. Linezolid resistant Staphylococcus aureus isolated from 2006 through 2008 at six hospitals in Japan. J. Infect. Chemother.17(1), 45–51 (2011).
   PubMed Web of Science ®Google Scholar
• Gao W, Chua K, Davies JK et al. Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog.6, e1000944 (2010).
   PubMed Web of Science ®Google Scholar
• Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance; results from 5591 gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis.64, 191–201 (2009).
   PubMed Web of Science ®Google Scholar
• Long KS, Poeshlgaard J, C, Schwarz S, Vester B. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob. Agents Chemother.50(7), 2500–2505 (2006).
   PubMed Web of Science ®Google Scholar
• Kehrenberg C, Cuny C, Strommenger B, Schwarz S, Witte W. Methicillin-resistant and susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. Antimicrob. Agents Chemother.53(2), 779–781 (2009).
   PubMed Web of Science ®Google Scholar
• Mendes RE, Deshpande LM, Castanheira M, Dipersio J, Saubolle MA, Jones RN. First report of cfr-mediated resi stance to linezolid in human staphylococcal clinical isolates in the United States. Antimicrob. Agents Chemother.52, 2244–2246 (2008).
   PubMed Web of Science ®Google Scholar
• Morales G, Picazo JJ, Baos E et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin. Infect. Dis.50, 821–825 (2010).
   PubMed Web of Science ®Google Scholar
• Kehrenberg C, Aarestrup PM, Schwarz S. IS21–558 insertion sequences are involved in the mobility of the multiresistance gene cfr. Antimicrob. Agents Chemother.51, 483–487 (2007).
   PubMed Web of Science ®Google Scholar
• Bonilla H, Huband M, Seidel J et al. Multicity out break of linezolid resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. Clin. Infect. Dis.51, 796–800 (2010).
   PubMed Web of Science ®Google Scholar
• Sánchez-Garcia M, De la Torre MA, Morales G et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA303(22), 2260–2264 (2010).
   PubMed Web of Science ®Google Scholar
• Moellering RC Jr. Enterococcus species, Streptococcus bovis and Leuconostoc species. In: Principles and Practice of Infectious Diseases (Volume 1). Mandell GL, Bennett JE, Dolin R (Eds). Elsevier Churchill Livingstone, PA, USA, 2411–5421 (2005).
   Google Scholar
• Ziraqzadesh A, Patel R. Vancomycin-resistant enterococci colonization, infection, detection and treatment. Mayo Clin. Proc.81, 529–536 (2006).
   PubMed Web of Science ®Google Scholar
• Brown DFJ, Brown NM, Cookson BD et al. National glycopeptide-resistant enterococcal bacteraemia surveillance working group report to the Department of Health – August 2004. J. Hosp. Infect.62, S1–S27 (2006).
   PubMed Web of Science ®Google Scholar
• Hayden MK, Trenholme GM, Schultz JE, Sahm DF. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate. J. Infect. Dis.167(5), 1224–1227 (1993).
   PubMed Web of Science ®Google Scholar
• Leclercq R. Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci. Clin. Microbiol. Infect.15, 224–231 (2009).
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch. Intern. Med.162, 2223–2228 (2002).
   PubMed Web of Science ®Google Scholar
• Salgado CD. The risk of developing a vancomycin-resistant enterococcus bloodstream infection for colonized patients. Am. J. Infect. Control36, S175, e5–e175, e8 (2008).
   PubMedGoogle Scholar
• Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev. Anti Infect. Ther.6(5), 637–655 (2008).
   PubMed Web of Science ®Google Scholar
• Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant Enterococcus infection in the United States. Infect. Control Hosp. Epidemiol.30, 184–186 (2009).
   PubMed Web of Science ®Google Scholar
• Reik R, Tenover FC, Klein E, McDonald LC. The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004. Diagn. Microbiol. Infect. Dis.62, 81–85 (2008).
   PubMed Web of Science ®Google Scholar
• Werner G, Coque TM, Hammerum AM. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill.13, pii 9046 (2008).
   Google Scholar
• Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis.58, 163–170 (2007).
   PubMed Web of Science ®Google Scholar
• Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect. Control Hosp. Epidemiol.24, 690–698 (2003).
   PubMed Web of Science ®Google Scholar
• Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch. Intern. Med.158(5), 522–527 (1998).
   PubMed Web of Science ®Google Scholar
• Song X, Srinivasan A, Plaut D, Perl TM. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay and costs. Infect. Control Hosp. Epidemiol.24, 251–256 (2003).
   PubMed Web of Science ®Google Scholar
• Hautemaniere A, Hunter PR, Diguio N, Albuisson E, Hartemenn P. A prospective study of the impact of colonization following hospital admission by glycopeptide-resistant enterococci on mortality during a hospital outbreak. Am. J. Infect. Control37(9), 746–752 (2009).
   PubMed Web of Science ®Google Scholar
• Sakka V, Tsiodras S, Galani L et al. Risk factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. Clin. Microbiol. Infect.14(1), 14–21 (2008).
   PubMed Web of Science ®Google Scholar
• Diaz Granados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin. Infect. Dis.41, 327–333 (2005).
   PubMed Web of Science ®Google Scholar
• Gavaldà J, Len O, Mirò JM, Munoz P, Montejo M, Alarcòn A. Brief communication: treatment of Enterococcusfaecalis endocarditis with ampicillin plus ceftriaxone. Ann. Intern. Med.146, 574–579 (2007).
   PubMedGoogle Scholar
• Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J. Antimicrob. Chemother.65, 1126–1136 (2010).
   PubMed Web of Science ®Google Scholar
• Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against Gram-positive cocci. J. Chemther.18, 27–32 (2006).
   PubMed Web of Science ®Google Scholar
• Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill.13, pii 19044 (2008).
   Google Scholar
• Pitout JDD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis.8, 159–166 (2008).
   PubMed Web of Science ®Google Scholar
• Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int. J. Med. Microbiol.300(6), 371–379 (2010).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother.59, 165–174 (2007).
   PubMed Web of Science ®Google Scholar
• Chia JH, Su LH, Lee MH et al. Development of high-level carbapenem resistance in Klebsiella pneumoniae among patients with prolonged hospitalization and carbapenem exposure. Microb. Drug Resist.16(4), 317–325 (2010).
   PubMed Web of Science ®Google Scholar
• Garcia-Fernàndez A, Miriagou V, Papagiannitsis CC et al. An ertapenem-resistant extended-spectrum-β-lactamases-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant. Antimicrob. Agents Chemother.54(19), 4178–4184 (2010).
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemase (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother.65, 1119–1125 (2010).
   PubMed Web of Science ®Google Scholar
• Noordman P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis.9, 228–236 (2009).
   PubMed Web of Science ®Google Scholar
• Grundmann H, Livermore DM, Giske CG et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill.15(46), pii 19711 (2010).
   Google Scholar
• Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis.9, 597–602 (2010).
   Google Scholar
• Falcone M, Mezzatesta ML, Perilli M et al. VIM-1 metallo-β-lactamase producing Enterobacter cloacae infections and their correlation with clinical outcome. J. Clin. Microbiol.47, 3514–3519 (2009).
   PubMed Web of Science ®Google Scholar
• Maltezou HC. Metallo-β-lactamases in Gram-negative bacteria: introducing the era of pan-resistance? Int. J. Antimicrob. Agents33, 405.e1–7 (2009).
   PubMed Web of Science ®Google Scholar
• Leavitt A, Chmelnitsky I, Ofek I, Carmeli Y, Navon-Venezia S. Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic Klebsiella pneumoniae strain. J. Antimicrob. Chemother.65(2), 243–248 (2010).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents35(3), 240–243 (2010).
   PubMed Web of Science ®Google Scholar
• Brink A, Feldman C, Richards G, Moolman J, Senekal M. Emergence of extensive drug resistance (XDR) among Gram-negative bacilli in South Africa looms nearer. S. Afr. Med. J.98(8), 586 (2008).
   PubMed Web of Science ®Google Scholar
• Rhee JY, Park YK, Shin JY et al. KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea. Antimicrob. Agents Chemother.54(5), 2278–2279 (2010).
   PubMed Web of Science ®Google Scholar
• Kontopoulou K, Protonotariou E, Vasilakos K et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 β-lactamase resistant to colistin. J. Hosp. Infect.76(1), 70–73 (2010).
   PubMed Web of Science ®Google Scholar
• Hentscke M, Wolters M, Sobottka I, Rohde H, Aepfelbacher M. ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline. Antimicrob. Agents Chemother.54(6), 2720–2723 (2010).
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev. Pharmacoecon. Outcomes Res.10(4), 441–451 (2010).
   PubMed Web of Science ®Google Scholar
• Towner KJ. Acinetobacter: an old friend, but a new enemy. J. Hosp. Infect.73, 355–363 (2009).
   PubMed Web of Science ®Google Scholar
• Grossi P, Dalla Gasperina D. Treatment of Pseudomonas aeruginosa infection in critically ill patients. Expert Rev. Anti Infect. Ther.4(4), 639–662 (2006).
   PubMedGoogle Scholar
• McGowan JE Jr. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am. J. Med.119, S29–S36 (2006).
   PubMed Web of Science ®Google Scholar
• Rice LB. Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. Cleve. Clin. J. Med.74, S12–S20 (2007).
   PubMedGoogle Scholar
• Rice LB. The clinical consequences of antimicrobial resistance. Curr. Opin. Microbiol.12, 476–481 (2009).
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill.13(47), pii 19045 (2008).
   Google Scholar
• Moffatt GH, Harper M, Harrison P et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother.54(12), 4971–4977 (2010).
   PubMed Web of Science ®Google Scholar
• Giamarellou H, Antoniadou A, Kanellakopoulou K. Acinetobacter baumannii: a universal threat to public health? Int. J. Antimicrob. Agents32(2), 106–119 (2008).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Carvalhaes CG, Picao RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev. Anti Infect. Ther.8(1), 71–93 (2010).
   PubMed Web of Science ®Google Scholar
• Crossman IC, Gould VC, Dow JM et al. The complex genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistant determinants. Genome Biol.9(4), R74 (2008).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol.55, 1619–1629 (2006).
   PubMed Web of Science ®Google Scholar
• Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob. Agents Chemother.52(3), 813–821 (2008).
   PubMed Web of Science ®Google Scholar
• Kallen AJ, Hidron AI, Patel J, Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006–2008. Infect. Control Hosp. Epidemiol.31(5), 528–531 (2010).
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54371 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004). Clin. Microbiol. Infect.12, 315–321 (2006).
   PubMed Web of Science ®Google Scholar
• Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus–baumannii complex and Enterobacteriaceae collected as part of the Tygecycline evaluation and surveillance trial. J. Infect.55, 49–57 (2007).
   PubMed Web of Science ®Google Scholar
• Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin America collected as part of TEST and the in vitro activity of tigecycline. J. Antimicrob. Chemother.60, 1018–1029 (2007).
   PubMed Web of Science ®Google Scholar
• Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977–2000. Infect. Control Hosp. Epidemiol.24, 284–295 (2003).
   PubMed Web of Science ®Google Scholar
• Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect. Dis.6, 130 (2006).
   PubMed Web of Science ®Google Scholar
• Saeed S, Fakih MG, Riederer K, Shah AR, Khatib R. Interinstitutional and intrainstitutional transmission of a strain of Acinetobacter baumannii detected by molecular analysis: comparison of pulsed-field gel electrophoresis and repetitive sequence-based polymerase chain reaction. Infect. Control Hosp. Epidemiol.27, 981–983 (2006).
   PubMed Web of Science ®Google Scholar
• Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis.42, 692–699 (2006).
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DR, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J. Antimicrob. Chemother.62(1), 45–55 (2008).
   PubMed Web of Science ®Google Scholar
• Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother.51(10), 3471–3484 (2007).
   PubMed Web of Science ®Google Scholar
• Sunenshine RH, Wright MO, Maragakis LL et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg. Infect. Dis.13(1), 97–103 (2007).
   PubMed Web of Science ®Google Scholar
• Richet H, Fournier PE. Nosocomial infections caused by Acinetobacter baumannii: a major threat worldwide. Infect. Control Hosp. Epidemiol.27(7), 645–646 (2006).
   PubMed Web of Science ®Google Scholar
• Gootz TD, Marra A. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev. Anti Infect. Ther.6(3), 309–325 (2008).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kopteridis P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J. Hosp. Infect.64, 7–15 (2006).
   PubMed Web of Science ®Google Scholar
• Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother.50(1), 43–48 (2006).
   PubMed Web of Science ®Google Scholar
• Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am. J. Med.119(6), 526, e19–e526, e25 (2006).
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol.27(9), 893–900 (2006).
   PubMed Web of Science ®Google Scholar
• Maragakis LL. Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Crit. Care Med.38(Suppl.), S345–S351 (2010).
   PubMed Web of Science ®Google Scholar
• Lee NY, Lee HC, Chang CM, Shih HI, Wu CJ, Ko WC. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect. Control Hosp. Epidemiol.28(6), 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteraemia on patient outcomes. Antimicrob. Agents Chemother.54(9), 3717–3722 (2010).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int. J. Antimicrob. Agents29, 9–25 (2007).
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos DR, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis.8, 751–762 (2008).
   PubMed Web of Science ®Google Scholar
• Ng J, Gosbell IB, Kelly JA, Boyle MJ, Ferguson JK. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J. Antimicrob. Chemother.58, 1078–1081 (2006).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii. Emergence of a successful pathogen. Clin. Microbiol. Rev.21(3), 538–582 (2008).
   PubMed Web of Science ®Google Scholar
• Orsi GB, Franchi C, Giordano A et al. Multidrug resistant Acinetobacter baumannii in an intensive care unit. J. Chemother.20, 219–224 (2008).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit. Care10, R48 (2006).
   PubMed Web of Science ®Google Scholar
• Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit. Care Med.37, 1463–1469 (2009).
   PubMed Web of Science ®Google Scholar
• Micozzi A, Venditti M, Monaco M et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hemathologica malignancies. Clin. Infect. Dis.31, 705–711, (2000).
   PubMed Web of Science ®Google Scholar
• Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrobial Agents Chemother.49, 3980–3981 (2005).
   PubMed Web of Science ®Google Scholar
• Borer A, Saidel-Odes L, Riesenberg K et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect. Control Hosp. Epidemiol.30, 972–976 (2009).
   PubMed Web of Science ®Google Scholar
• Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol.30, 1180–1185 (2009).
   PubMed Web of Science ®Google Scholar
• Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol.29, 1099–1106 (2008).
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob. Agents Chemother.52(3), 1028–1033 (2008).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Barth AL, Fernandes JF, Moro AL, Goncalves AL, Goldani LZ. Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortalità in the era of metallo-β-lactamase-mediated multidrug resistance: a prospective observational study. Crit. Care10(4), R114 (2006).
   PubMed Web of Science ®Google Scholar
• Georges B, Conil JM, Dubouix A et al. Risk of emergence of Pseudomonas aeruginosa resistance to β-lactam antibiotics in intensive care units. Crit. Care Med.34(6), 1636–1641 (2006).
   PubMed Web of Science ®Google Scholar
• Zavascki M, Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur. J. Clin. Microbiol. Infect. Dis.29, 127–142 (2010).
   PubMed Web of Science ®Google Scholar
• Dellit TH, Owens RC, McGowan JE Jr et al. Infectious diseases of North America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program of enhance antimicrobial stewardship. Clin. Infect. Dis.44, 159–177 (2007).
   PubMed Web of Science ®Google Scholar
• Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N. Engl. J. Med.362, 1804–1813 (2010).
   PubMed Web of Science ®Google Scholar
• Orsi GB, Garcìa-Fernàndez A, Giordano A et al. Risk factors and clinical significance of ertapenem resistant Klebsiella pneumoniae in hospitalized patients. J. Hosp. Infect.78(1), 54–58 (2011).
   PubMed Web of Science ®Google Scholar
• Miriagou V, Cornaglia G, Edelstein M et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin. Microbiol. Infect.16, 112–122 (2010).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Meshtaq S Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem resistant Enterobacteriaceae isolates. J. Antimicrob. Agents66, 48–53 (2011).
   Google Scholar
• Livermore DM, Meshtaq S Warner M et al. Activity of NXL104 combinations with ceftazidime and aztreonam against carbapenemase producing Enterobacteriaceae. Antimicrob. Agents Chemother.55, 390–394 (2011).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq. What remains against carbapenem-resistant Enetrobacteraceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int. J. Antimicrob. Agents37(5), 415–419 (2011).
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis.6(9), 589–601 (2006).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother.60, 1206–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Kwa AL, Lim TP, Low JG et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn. Microbiol. Infect. Dis.60(2), 163–167 (2008).
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob. Agents Chemother.53(8), 3430–3436 (2009).
   PubMed Web of Science ®Google Scholar
• Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin. Microbiol. Rev.21(3), 449–465 (2008).
   PubMed Web of Science ®Google Scholar
• Imberti R, Cusati M, Villani P et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest138, 1333–1339 (2010).
   PubMed Web of Science ®Google Scholar
• Lu Q, Girardi C, Zhang M et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med.54(9), 3702–3707 (2010).
   Google Scholar
• Rattanaumpawan P, Lorsutthitham J, Ungprasert P et al. Randomized controlled trial nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J. Antimicrob. Chemother.65(12), 2645–2649 (2010).
   PubMed Web of Science ®Google Scholar
• Kofteridis DP, Alexopoulo C, Valakis A et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched-control study. Clin. Infect. Dis.51(11), 1238–1244 (2010).
   PubMed Web of Science ®Google Scholar
• Cascio A, Conti A, Sinardi L et al. Post-neurosufgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int. J. Infect. Dis.14(7), e572–e579 (2010).
   PubMed Web of Science ®Google Scholar
• Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother.63(4), 775–780 (2009).
   PubMed Web of Science ®Google Scholar
• Metan G, Alp E, Yildiz O et al. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections. J. Chemother.22(2), 110–114 (2010).
   PubMed Web of Science ®Google Scholar
• Poulakou G, Kontopidou FV, Paramythiotou E et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J. Infect.58(4), 273–284 (2009).
   PubMed Web of Science ®Google Scholar
• Gardiner D, Dukart G, Cooper A, Babinchat T. Safety and efficacy of intravenous tigecycline with subjects with secondary bacteremia: pooled results from eight Phase III clinical trials. Clin. Infect. Dis.50, 229–238 (2010).
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob. Agents Chemother.55(2), 1162–1172 (2011).
   PubMed Web of Science ®Google Scholar
• Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J. Clin. Microbiol.47(5), 1613 (2009).
   PubMed Web of Science ®Google Scholar
• Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int. J. Antimicrob. Agents34, 101–102 (2009).
   PubMed Web of Science ®Google Scholar
• Welte T, Pletz MW. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int. J. Antimicrob. Agents39, 391–400 (2010).
   Google Scholar
• Chemaly RF, Hanmod SS, Jiang Y et al. Tigecycline use in cancer patients with serious infections: report of 110 cases from a single institution. Medicine (Baltimore)88, 211–220 (2009).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect. Dis.10, 287 (2010).
   PubMed Web of Science ®Google Scholar
• Curcio D, Vargas SW, Ugarte Ubiergo S et al. Tigecycline treatment of critically ill patients: the Latin user experience. Curr. Clin. Pharmacol.6(1), 18–25 (2011).
   PubMedGoogle Scholar
• Humphries RM, Kelesidis T, Dien Bard J, Ward KW, Bhattacharya D, Lewinski MA. Successful treatment of pan-resitant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin. J. Med. Microbiol.59, 1383–1386 (2010).
   PubMed Web of Science ®Google Scholar
• Principe L, D’Arezzo S, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann. Clin. Microbiol. Antimicrob.8, 18 (2009).
   PubMed Web of Science ®Google Scholar
• Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother.53(5), 1868–1873 (2009).
   PubMed Web of Science ®Google Scholar
• Pournaras S, Vrioni G, Neou E et al. Activity of tigecycline alone and in combimation with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int. J. Antimicrob. Agents37(3), 244–247 (2011).
   PubMed Web of Science ®Google Scholar
• Nguyen M, Eschenauer GA, Bryan M et al. Carbapenem resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn. Microbiol. Infect. Dis.67, 180–184 (2010).
   PubMed Web of Science ®Google Scholar
• Lee J, Patel G, Huprikar S, Calfee DP. Decreased susceptibility to polimixin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J. Clin. Microbiol.47, 1611–1612 (2009).
   PubMed Web of Science ®Google Scholar
• Endimiani A, Patel G, Hujer KM et al.In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonscusceptible to tigecycline and/or colistin. Antimicrob. Agents Chemother.54, 526–529 (2010).
   PubMed Web of Science ®Google Scholar
• Popovic M, Steinort D, Pillai S et al. Antimicrobial susceptibility of gram negative non urinary bacteria to fosfomycin and other antimicrobials. Future Microbiol.5, 961–970 (2010).
   PubMed Web of Science ®Google Scholar
• Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes LD, Falagas ME. Synergy of fosfomycin with other antibiotics for Gram positive and Gram negative bacteria. Eur. J. Clin. Pharmacol.66, 359–368 (2010).
   PubMed Web of Science ®Google Scholar
• Matzi V, Lindenmann J, Porubsky C et al. Extracellular concentration of fosfomycin in lung tissue of septic patients. J. Antimicrob. Chemother.65, 995–998 (2010).
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Virtzili S, Rafailidis P, Chavelelakis G, Damala M, Falagas ME. Intravenous forfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect.16, 184–186 (2010).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J. Antimicrob. Chemother.62(5), 889–894, (2008).
   PubMed Web of Science ®Google Scholar
• Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur. J. Microbiol. Infect. Dis.26(4), 229–237 (2007).
   PubMed Web of Science ®Google Scholar
• Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Practices Committee. Management of multidrug-resistant organisms in health care settings. Am. J. Infect. Control35, S165–193 (2007).
   PubMed Web of Science ®Google Scholar
• Tacconelli E. Screening and isolation for infection control. J. Hosp. Infect.73, 371–377 (2009).
   PubMed Web of Science ®Google Scholar
• Binkley S, Fishman NO, La Rosa LA et al. Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy. Infect. Control Hosp. Epidemiol.27(7), 682–687 (2006).
   PubMed Web of Science ®Google Scholar
• Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA Guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect. Control Hosp. Epidemiol.24, 362–386 (2003).
   PubMed Web of Science ®Google Scholar
• Lucet JC, Grenet K, Armand-Lefevre L et al. High prevalence of carriage of methicillin resistant Staphylococcus aureus at hospital admission in elderly patients: implications for infection control strategies. Infect. Control Hosp. Epidemiol.26, 121–126 (2005).
   PubMed Web of Science ®Google Scholar
• Ostrowsky BE, Trick WE, Sohn AH et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N. Engl. J. Med.344(19), 1427–1433 (2001).
   PubMed Web of Science ®Google Scholar
• Huang SS, Rifas-Shiman SL, Warren DK et al. Improving methicillin-resistant Staphylococcus aureus surveillance and reporting in intensive care units. J. Infect. Dis.195, 330–338 (2007).
   PubMed Web of Science ®Google Scholar
• Patel M, Weinheimer JD, Waites KB, Baddley JW. Active surveillance to determine the impact of methicillin-resistant Staphylococcus aureus colonization on patients in intensive care units of a veterans affairs medical center. Infect. Control Hosp. Epidemiol.29, 503–509 (2008).
   PubMed Web of Science ®Google Scholar
• Weber SG, Huang SS, Oriola S et al. Legislative mandaes for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC task force. Am. J. Infect. Control.35(2), 73–85 (2007).
   PubMed Web of Science ®Google Scholar
• McGinigle KL, Gourlay ML, Buchanan IB. The use of active surveillance cultures in adult intensive care units to reduce methicillin-resistant Staphylococcus aureus-related morbidity, mortality and costs: a systematic review. Clin. Infect. Dis.46, 1717–1725 (2008).
   PubMed Web of Science ®Google Scholar
• Wernitz MH, Keck S, Swidsinski S, Schulz S, Veit SK. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin. Microbiol. Infect.11, 466–471 (2005).
   PubMed Web of Science ®Google Scholar
• Cooper BS, Stone SP, Kibbler CC et al. Isolation measures in the hospital management of methicillin resistant Staphylococcus aureus (MRSA): systematic review of the literature. BMJ329(7465), 533 (2004).
   PubMed Web of Science ®Google Scholar
• Cepeda JA, Whitehouse T, Cooper B et al. Isolation of patients in single rooms or cohorts to reduce spread of MRSA in intensive care units: prospective two-centre study. Lancet365(9456), 295–304 (2005).
   PubMed Web of Science ®Google Scholar
• Nijssen S, Bonten MJ, Weinstein RA. Are active microbiological surveillance and subsequent isolation needed to prevent the spread of methicillin-resistant Staphylococcus aureus? Clin. Infect. Dis.40, 405–409 (2005).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Edmond MB. Look before you leap: active surveillance for multidrug-resistant organisms. Clin. Infect. Dis.44, 1101–1107 (2007).
   PubMed Web of Science ®Google Scholar
• Harris AD, Furuno JP, Roghman MC et al. targeted surveillance of methicillin-resistant Staphylococcus aureus and its potential use to guide empiric antibiotic therapy. Antimicrob. Agents Chemother.54, 3143–3148 (2010).
   PubMed Web of Science ®Google Scholar
• Strausbaugh LJ, Siegel JD, Weinstein RA. Preventing transmission of multidrug-resistant bacteria in health care settings: a tale of 2 guidelines. Clin. Infect. Dis.42, 828–835 (2006).
   PubMed Web of Science ®Google Scholar
• Santos RP, Mayo TW, Siegel JD. Active surveillance cultures and contact precautions for control of multidrug-resistant organisms: ethical considerations. Clin. Infect. Dis.47, 110–116 (2008).
   PubMed Web of Science ®Google Scholar
• Harbarth S, Frankhauser C, Schrenzel J et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA299(10), 1149–1157 (2008).
   PubMed Web of Science ®Google Scholar
• Carroll MC. Rapid diagnostics for methicillin-resistant Staphylococcus aureus: current status. Mol. Diagn. Ther.12, 15–24 (2008).
   PubMed Web of Science ®Google Scholar
• French GL. Methods for screening for methicillin-resistant Staphylococcus aureus carriage. Clin. Microbiol.15(Suppl. 7), 10–16 (2009).
   Google Scholar
• Tacconelli E, De Angelis G, de Waure C, Cataldo MA, La Torre G, Cauda R. Rapid screening tests for methicillin-resistant Staphylococcus aureus at hospital admission: systematic review and meta-analysis. Lancet Infect. Dis.9, 546–554 (2010).
   Web of Science ®Google Scholar
• Stamper PD, Cai M, Lema C, Eskey K, Carroll KC. Comparison of the BD GeneOhm VanR assay to culture for identification of vancomycin-resistant enterococci in rectal and stool specimens. J. Clin. Microbiol.45, 3360–3365 (2007).
   PubMed Web of Science ®Google Scholar
• Haber M, Levin BR, Kramarz P. Antibiotic control of antibiotic resistance in hospitals: a simulation study. BMC Infect. Dis.10, 254 (2010).
   PubMed Web of Science ®Google Scholar
• Furuno JP, Perencevich EN, Johnson JA et al. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci co-colonization. Emerg. Infect. Dis.11, 1539–1544 (2005).
   PubMed Web of Science ®Google Scholar
• Han SH, Chin BS, Lee HS et al. Recovery of both vancomycin.resistant enterococci and methicillin-resistant Staphylococcus aureus from culture of a single clinical specimen from colonized or infected patients. Infect. Control Hosp. Epidemiol.30(2), 130–138 (2009).
   PubMed Web of Science ®Google Scholar
• Larson EL, Cohen B, Ross B, Behta M. Isolation precautions for methicillin-resistant Staphylococcus aureus: electronic surveillance to monitor adherence. Am. J. Crit. Care19, 16–26 (2010).
   PubMed Web of Science ®Google Scholar
• Pittet D, Hugonnet S, Harbarth S et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Program. Lancet356, 1307–1312 (2000).
   PubMed Web of Science ®Google Scholar
• Grayson ML, Jarvie LJ, Martin R et al. Significant reductions in methicillin-resistant Staphylococcus aureus bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. Med. J. Aust.188(11), 633–640 (2008).
   PubMed Web of Science ®Google Scholar
• Pessoa-Silva CL, Hugonnet S, Pfister R et al. Reduction of health care associated infection risk in neonatos by successful hand hygiene promotion. Pediatrics120(2), e382–e390 (2007).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Garcia L, Ramirez E et al. Long-tertm control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive “bundle” approach. Am. J. Infect. Control37(9), 715–722 (2009).
   PubMed Web of Science ®Google Scholar
• Longtin Y, Sax H, Allegranzi B et al. Hand Hygiene. N. Engl. J. Med.364, e24 (2011).
   PubMedGoogle Scholar
• Sax H, Allegranzi B, Uckay I et al. My five moments for hand hygiene: a user-centred design approach to understand, train, monitor and report hygiene. J. Hosp. Infect.67, 9–21 (2007).
   PubMed Web of Science ®Google Scholar
• Sroka S, Gastmeier P, Meyer E. Impact of alcohol hand-rub use on methicillin-resistant Staphylococcus aureus: an analysis of the literature. J. Hosp. Infect.74(3), 204–211 (2010).
   PubMed Web of Science ®Google Scholar
• Harbarth S, Pittet D. Infection prevention research in Europe: recent advances and future priorities. Infect. Control Hosp. Epidemiol.31(Suppl. 1), S11–S13 (2010).
   PubMed Web of Science ®Google Scholar
• Duckro AN, Blom DW, Lyle EA, Weinstein RA, Hayden MK. Transfer of vancomycin-resistant enterococci via health care worker hands. Arch. Intern. Med.165(3), 302–307 (2005).
   PubMedGoogle Scholar
• Huang R, Mehta S, Weed D, Price CS. Methicillin-resistant Staphylococcus aureus survival on hospital fomites. Infect. Control Hosp. Epidemiol.27(11), 1267–1269 (2006).
   PubMed Web of Science ®Google Scholar
• Williams C, Davis DL. Methicillin-resistant Staphylococcus aureus fomite survival. Clin. Lab. Sci.22(1), 34–38 (2009).
   PubMedGoogle Scholar
• Marchaim D, Navon-Venezia S, Schwartz D et al. Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J. Clin. Microbiol.45(5), 1551–1555 (2007).
   PubMed Web of Science ®Google Scholar
• Gasink LB, Singer K, Fishman NO et al. Contact isolation for infection in hospitalized patients: is patient satisfaction affected? Infect. Control Hosp. Epidemiol.29(3), 275–278 (2008).
   PubMed Web of Science ®Google Scholar
• West TE, Guerry C, Hiott M, Morrow N, Ward K, Salgado CD. Effect of targeted surveillance for control of methicillin-resistant Staphylococcus aureus in a community hospital system. Infect. Control Hosp. Epidemiol.27(3), 233–238 (2006).
   PubMed Web of Science ®Google Scholar
• Conterno LO, Shymanski J, Ramotar K et al. Real-time polymerase chain reaction detection of methicilin-resistant Staphylococcus aureus: impact on nosocomial transmission and costs. Infect. Control Hosp. Epidemiol.28(10), 1134–1141 (2007).
   PubMed Web of Science ®Google Scholar
• Coia JE, Duckworth GJ, Edwards DI et al. Guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J. Hosp. Infect.63S, S1–S44 (2006).
   Google Scholar
• Tacconelli E. Methicillin-resistant Staphylococcus aureus: source control and surveillance organization. Clin. Microbiol. Infect.15(Suppl. 7), 31–38 (2009).
   PubMed Web of Science ®Google Scholar
• Gould IM, MacKenzie FM, MacLennan G, Pacitti D, Watson EJ, Noble DW. Topical antimicrobials in combination with admission screening and barrier precautions to control endemic methicillin-resistant Staphylococcus aureus in an intensive care unit. Int. J. Antimicrob. Agents29(5), 536–543 (2007).
   PubMed Web of Science ®Google Scholar
• Sandri AM, Delarosa MG, Ruschel de Alcantara L, da Silva Elias L, Zavascki AP. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect. Control Hosp. Epidemiol.27(2), 185–187 (2006).
   PubMed Web of Science ®Google Scholar
• Simor AE, Phillips E, McGeer A et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin and rifampicin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin. Infect. Dis.44(2), 178–185 (2007).
   PubMed Web of Science ®Google Scholar
• Vernon MO, Hayden MK, Trick WE et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vanomycin-resistant enterococci. Arch. Intern. Med.166(3), 306–312 (2006).
   PubMedGoogle Scholar
• Albrich WC, Harbarth S. Health-care workers: source, vector or victim of MRSA? Lancet Infect. Dis.8(5), 289–301 (2008).
   PubMed Web of Science ®Google Scholar
• Simpson AH, Dave J, Cookson B. The value of routine screening of staff for MRSA. J. Bone Joint Surg. Br.89(5), 565–566 (2007).
   PubMedGoogle Scholar
• Dancer SJ. The role of environmental cleaning in the control of hospital-acquired infection. J. Hosp. Infect.73(4), 378–385 (2009).
   PubMed Web of Science ®Google Scholar
• Trillis F 3rd, Eckstein EC, Budavich R, Pultz MJ, Donskey CJ. Contamination of hospital curtains with healthcare-associated pathogens. Infect. Control Hosp. Epidemiol.29(1), 1074–1076 (2008).
   PubMed Web of Science ®Google Scholar
• Hardy KJ, Oppenheim BA, Gossain S, Gao F, Hawkey PM. A study of the relantionship between environmental contamination with methicillin-resistant Staphylococcus aureus (MRSA) and patients acquisition of MRSA. Infect. Control Hosp. Epidemiol.27(2), 127–132 (2006).
   PubMed Web of Science ®Google Scholar
• De Lassence A, Hidri N, Timsit JF et al. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin. Infect. Dis.42(2), 170–178 (2006).
   PubMed Web of Science ®Google Scholar
• Hayden MK, Bonten MJ, Blom DW, Lyle EA, van de Vijver DA, Weinstein RA. Reduction in acquisition of vanomycin-resistant enterococcus after enforcement of routine environmental cleaning measures. Clin. Infect. Dis.42(11), 1552–1560 (2006).
   PubMed Web of Science ®Google Scholar
• Hayden MK, Blom DW, Lyle EA, Moore CG, Weinstein RA. Risk of hand or glove contamination after contact with patients colonized with vancomycin-resistant enterococcus or the colonized patients environment. Infect. Control Hosp. Epidemiol.29(2), 149–154 (2008).
   PubMed Web of Science ®Google Scholar
• Fishman N. Antimicrobial stewardship. Am. J. Med.119, S53–S61 (2006).
   PubMed Web of Science ®Google Scholar
• Tacconelli E, De Angelis G, Cataldo MA, Pozzi E, Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J. Antimicrob. Chemother.61, 26–38 (2008).
   PubMed Web of Science ®Google Scholar
• Lodise TP, Miller C, Patel N, Graves J, McNutt LA. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates. Infect. Control Hosp. Epidemiol.28, 959–965 (2007).
   PubMed Web of Science ®Google Scholar
• MacAdam H, Zaoutis TE, Gasink LB, Bilker WB, Lautenbach E. Investigating the association between antibiotic use and antibiotic resistance: impact of different methods of categorising prior antibiotic use. Int. J. Antimicrob. Agents28, 325–332 (2006).
   PubMed Web of Science ®Google Scholar
• D’Agata EMC, Cataldo MA, Cauda R, Tacconelli E. The importance of addressing multidrug resistance and not assumine single-drug resistance in case–control studies. Infect. Control Hosp. Epidemiol.27(7), 670–674 (2006).
   PubMed Web of Science ®Google Scholar
• Tacconelli E, De Angelis G, Cataldo MA et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob. Agents Chemother.53(10), 4264–4269 (2009).
   PubMed Web of Science ®Google Scholar
• Owens RC, Rice L. Hospital-based strategies for combating resistance. Clin. Infect. Dis.42, S173–S181 (2006).
   PubMed Web of Science ®Google Scholar
• Pulcini C, Defres S, Aggarwal I, Nathwani D, Davey P. Design of a “day 3 bundle” to improbe the reassesment of inpatient empirical antibiotic prescriptions. J. Antimicrob. Chemother.61, 1384–1388 (2008).
   PubMed Web of Science ®Google Scholar
• Yong MK, Buising KL, Cheng AC, Thursky KA. Improved susceptibility of Gram-negative bacteria in an intensive care unit implementation of a computerized antibiotic decision support system. J. Antimicrob. Chemother.65, 1062–1069 (2010).
   PubMed Web of Science ®Google Scholar
• Davey P, Brown E, Fenelon L et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg. Infect. Dis.12(2), 211–216 (2006).
   PubMed Web of Science ®Google Scholar
• Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin. Infect. Dis.42(Suppl. 2), 4–16 (2006).
   Google Scholar
• Bergstrom CT, Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc. Natl Acad. Sci. USA101(36), 13285–13290 (2004).
   PubMed Web of Science ®Google Scholar
• Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin. Infect. Dis.43(Suppl. 2), S82–S88 (2006).
   PubMed Web of Science ®Google Scholar
• Zillich AJ, Sutherland JM, Wilson SJ, Diekema DJ, Ernst EJ, Vaughn TE. Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals. Infect. Control Hosp. Epidemiol.27(10), 1088–1095 (2006).
   PubMed Web of Science ®Google Scholar
• Drew RH. Antimicrobial stewardship programs: how to start and steer a successful program. J. Manag. Care Pharm.15(2), S18–S23 (2009).
   PubMed Web of Science ®Google Scholar
• Patel D, MacDougall C. How to make antimicrobial stewardship work: practical considerations for hospitals of all sizes. Hosp. Pharm.45(11 Suppl. 1), S10–S18 (2010).
   Google Scholar
• Goff DA. Antimicrobial stewardship: bridging the gap between quality care and cost. Curr. Opin. Infect. Dis.24(Suppl. 1), S11–S20 (2011).
   PubMed Web of Science ®Google Scholar
• Bouadma L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients exposure to antibiotics in intensive care units (PRORATA trial): has been tested in a multicentre randomised controlled trial. Lancet375, 463–474 (2010).
   PubMed Web of Science ®Google Scholar